The Research Triangle-headquartered solutions provider adds early-development formulation capabilities — the latest in a run of build-outs that has taken it from consultancy to end-to-end operator, including the cGMP device manufacturing space it stood up in King of Prussia last year.
Kymanox has opened a new formulation laboratory built to carry pharmaceutical and biotech clients from early research through manufacturing scale-up, the company announced. The facility adds specialized formulation development, analytical characterization, and process optimization for small molecules, biologics, and advanced therapy medicinal products (ATMPs) — spanning pulmonary, oral, injectable, transdermal, nasal, implantable, and ophthalmic delivery.
For a firm that has spent the better part of two decades as a consulting and technical-services partner, the Formulation Lab is another step in a deliberate shift toward owning the hands-on, physical work of drug development — not just advising on it.
What the lab does
The stated purpose is de-risking one of the hardest transitions in drug development: the handoff from R&D to commercial manufacturing. The lab is equipped to develop and characterize aqueous and non-aqueous formulations, suspensions, liposomes, and in situ gels.
On the hardware side, the facility runs biosafety level 2 biological safety cabinets, chemical fume hoods, temperature-controlled storage from -80°C to +40°C, ultrapure water systems, and process equipment including centrifuges, magnetic stirrers, and incubating shakers — enabling stability studies across the full storage range. Analytical work is available in-lab and through established partnerships for more advanced needs.
The lab is overseen by Ryan Doxey, Vice President of Technical Services, with a multidisciplinary team spanning CMC, pharmaceutical sciences, and process engineering across modalities.
“The Formulation Lab gives us hands-on capabilities to tackle critical formulation challenges across multiple modalities, from biologics stability to suspension uniformity to liposome characterization,” said Doxey. “Our in-house analytical suite means we can rapidly iterate and optimize formulations with real-time data, which is essential when clients need to de-risk their development path or prepare for manufacturing scale-up.”
The bigger pattern: consultancy to end-to-end operator
The Formulation Lab is easier to read as a milestone than a one-off. Kymanox, founded in 2004 and backed by Boston-based growth-equity firm WestView Capital Partners, has been steadily converting its consulting expertise into physical capacity and geographic footprint.
The through-line over the last few years:
- 2022 onward — international expansion into Germany, Switzerland, and Israel, layered on top of a U.S. presence anchored in Research Triangle Park with offices in Boston and the Philadelphia area.
- May 2025 — Kymanox stood up more than 5,000 square feet of newly constructed cGMP-compliant manufacturing space at its King of Prussia, Pennsylvania facility, delivering clinical devices designed, developed, and assembled in-house that went on to perform in human clinical studies. That launch effectively gave the firm a medical device and combination-product CDMO capability in the heart of Greater Philadelphia’s drug-delivery corridor.
- Early 2026 — an expansion of its CGxP laboratory space to meet projected demand and broaden testing services for clients, including Top 20 biopharma organizations.
- June 2026 — the Formulation Lab, adding early-stage development capability on both ends of the company’s U.S. footprint.
Each move has pushed Kymanox further along the product lifecycle it can service under one roof — from formulation optimization at the front end through device verification, human factors validation, and low-volume clinical manufacturing at the back.
Chief Operating Officer Nicholas Ciccarelli framed the lab in exactly those terms:
“The Formulation Lab creates a unique end-to-end capability for our clients, particularly those developing combination products and device-delivered therapies. We can now support the entire product development continuum, from formulation optimization through device verification and human factors validation, under one integrated service model. This seamless approach reduces handoff risks and accelerates time to market.”
The regional read
There’s a footprint story here worth naming. The new lab gives Kymanox physical capacity across two of the country’s most active life science regions — Research Triangle Park and Greater Philadelphia — and reinforces both.
King of Prussia already housed the GMP manufacturing space Kymanox built out in 2025 in one of the top device-and-delivery clusters – the Philadelphia suburbs – home to SHL Medical, PCI Pharma Services, and a dense bench of combination-product talent. In the Triangle, adding formulation capability there extends a home-region operation in one of the fastest-growing pharmaceutical and biotech manufacturing hubs in the U.S.
For the regional workforce, capacity build-outs like these are the quieter side of ecosystem growth. Wet-lab formulation scientists, CMC specialists, analytical chemists, and process engineers are precisely the roles a services firm has to staff and retain when it moves from advising to doing — and they tend to stay in-region, seeding expertise that compounds across the local talent base.
That is the pattern to watch. As more of the drug-development value chain gets built physically into RTP and Greater Philadelphia rather than contracted out elsewhere, the firms doing the building become part of the connective tissue holding these hubs together. Kymanox’s latest lab is one more brick in that wall.
More on the Formulation Lab is available at kymanox.com/formulation-lab.
BioBuzz covers the people, companies, and momentum shaping the life science ecosystem across the BioHealth Capital Region, Greater Philadelphia, and Research Triangle Park.
